546 related articles for article (PubMed ID: 10543326)
1. Red blood cell membrane lipid peroxidation and resistance to erythropoietin therapy in hemodialysis patients.
Gallucci MT; Lubrano R; Meloni C; Morosetti M; Manca di Villahermosa S; Scoppi P; Palombo G; Castello MA; Casciani CU
Clin Nephrol; 1999 Oct; 52(4):239-45. PubMed ID: 10543326
[TBL] [Abstract][Full Text] [Related]
2. Effects of a vitamin E-bonded membrane and of glutathione on anemia and erythropoietin requirements in hemodialysis patients.
Usberti M; Gerardi G; Micheli A; Tira P; Bufano G; Gaggia P; Movilli E; Cancarini GC; De Marinis S; D'Avolio G; Broccoli R; Manganoni A; Albertin A; Di Lorenzo D
J Nephrol; 2002; 15(5):558-64. PubMed ID: 12455724
[TBL] [Abstract][Full Text] [Related]
3. Does treatment of renal anemia with recombinant erythropoietin influence oxidative stress in hemodialysis patients?
Sommerburg O; Grune T; Hampl H; Riedel E; Ehrich JH; Siems WG
Clin Nephrol; 2000 Feb; 53(1 Suppl):S23-9. PubMed ID: 10746802
[TBL] [Abstract][Full Text] [Related]
4. Erythrocyte susceptibility to oxidative stress in chronic renal failure patients under different substitutive treatments.
Lucchi L; Bergamini S; Iannone A; Perrone S; Stipo L; Olmeda F; Caruso F; Tomasi A; Albertazzi A
Artif Organs; 2005 Jan; 29(1):67-72. PubMed ID: 15644086
[TBL] [Abstract][Full Text] [Related]
5. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
Nakamoto H; Mimura T; Honda N
Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
[TBL] [Abstract][Full Text] [Related]
6. ACE inhibitors or angiotensin II receptor blockers in dialysed patients and erythropoietin resistance.
Saudan P; Halabi G; Perneger T; Wasserfallen JB; Wauters JP; Martin PY;
J Nephrol; 2006; 19(1):91-6. PubMed ID: 16523432
[TBL] [Abstract][Full Text] [Related]
7. Lymphocyte 5'-nucleotidase and aminopeptidase N activity in patients on maintenance hemodialysis treated with human recombinant erythropoietin and 1-alpha-D3.
Stefanovic V; Mitić-Zlatkovic M; Radivojevic J; Vlahovic P
Ren Fail; 2005; 27(3):283-8. PubMed ID: 15957544
[TBL] [Abstract][Full Text] [Related]
8. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
[TBL] [Abstract][Full Text] [Related]
9. Managing erythropoietin hyporesponsiveness.
Kwack C; Balakrishnan VS
Semin Dial; 2006; 19(2):146-51. PubMed ID: 16551293
[TBL] [Abstract][Full Text] [Related]
10. Perturbation of autocrine/paracrine loops of burst-forming units of erythroid-derived cells in rHuEPO-hyporesponsive hemodialysis patients.
Nakao K; Wada J; Ota K; Ichikawa H; Akagi S; Okamoto A; Hida K; Nagake Y; Makino H
Am J Kidney Dis; 2003 Mar; 41(3):624-36. PubMed ID: 12612986
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human erythropoietin resistance in hemodialysis. Effects of paired filtration dialysis.
Carozzi S; Nasini MG; Santoni O; Tirotta A; Sanna A
ASAIO J; 1997; 43(5):M535-8. PubMed ID: 9360100
[TBL] [Abstract][Full Text] [Related]
12. Complete correction of renal anemia by recombinant human erythropoietin.
Ludat K; Paulitschke M; Riedel E; Hampl H
Clin Nephrol; 2000 Feb; 53(1 Suppl):S42-9. PubMed ID: 10746805
[TBL] [Abstract][Full Text] [Related]
13. Effect of recombinant human erythropoietin on insulin resistance in hemodialysis patients.
Khedr E; El-Sharkawy M; Abdulwahab S; Eldin EN; Ali M; Youssif A; Ahmed B
Hemodial Int; 2009 Jul; 13(3):340-6. PubMed ID: 19552740
[TBL] [Abstract][Full Text] [Related]
14. Soluble P-selectin during a single hemodialysis session in patients with chronic renal failure and erythropoietin treatment.
Stasko J; Galajda P; Ivanková J; Hollý P; Rozborilová E; Kubisz P
Clin Appl Thromb Hemost; 2007 Oct; 13(4):410-5. PubMed ID: 17911193
[TBL] [Abstract][Full Text] [Related]
15. Long-term erythropoietin therapy does not affect endothelial markers, coagulation activation and oxidative stress in haemodialyzed patients.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2007; 120(6):797-803. PubMed ID: 17391740
[TBL] [Abstract][Full Text] [Related]
16. Detection of circulating antierythropoietin antibodies in patients with end stage renal disease on regular hemodialysis.
El-Din MM; Attia FM; Labib SM; Omar W
Int J Lab Hematol; 2010 Jun; 32(3):336-43. PubMed ID: 19703235
[TBL] [Abstract][Full Text] [Related]
17. [Chronic inflammation, oxidative stress and effects of erythropoetin in end-stage renal disease patients].
Lazarević T; Stojimirović B; Poskurica M; Lazarević M; Mitrović N; Stolić R
Med Pregl; 2007; 60 Suppl 2():109-13. PubMed ID: 18928173
[TBL] [Abstract][Full Text] [Related]
18. Investigation of the efficacy of a biogeneric recombinant human erythropoietin alfa in the management of renal anemia in patients on hemodialysis: a multi-center clinical trial.
Beiraghdar F; Panahi Y; Einollahi B; Nemati E; Ghadiani MH; Sahebkar A; Maghsoudi N; Marzony ET
Clin Lab; 2012; 58(7-8):737-45. PubMed ID: 22997974
[TBL] [Abstract][Full Text] [Related]
19. Effect of exogenous reduced glutathione on the survival of red blood cells in hemodialyzed patients.
Usberti M; Lima G; Arisi M; Bufano G; D'Avanzo L; Gazzotti RM
J Nephrol; 1997; 10(5):261-5. PubMed ID: 9364318
[TBL] [Abstract][Full Text] [Related]
20. Administration of exogenous erythropoietin beta affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia.
Marsillach J; Martínez-Vea A; Marcas L; Mackness B; Mackness M; Ferré N; Joven J; Camps J
Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):347-9. PubMed ID: 17324148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
